Page last updated: 2024-09-21

4-Anilino-4-oxobutanoic acid

Cross-References

ID SourceID
PubMed CID7598
CHEMBL ID152730
CHEBI ID173931
SCHEMBL ID94252

Synonyms (59)

Synonym
CHEBI:173931
butanoic acid,4-oxo-4-(phenylamino)-
F0722-4214
n-phenyl-succinamic acid
nsc 56471
brn 2806264
4-oxo-4-(phenylamino)butanoic acid
nsc-56471
butanoic acid, 4-oxo-4-(phenylamino)-
n-phenylbutanedioic acid monoamide
succinanilic acid
nsc56471
succinamic acid, n-phenyl-
succinic monoanilide
propionic acid, 3-(phenylcarbamoyl)-
n-phenylsuccinamic acid
succinic acid monoanilide
102-14-7
OPREA1_552059
4-anilino-4-oxobutanoic acid
4-anilino-4-oxo-butanoic acid
OPREA1_388074
CHEMDIV2_000397
SR-01000418000-2
MAYBRIDGE1_006842
STK018310
bdbm50136839
CHEMBL152730 ,
AKOS000296139
HMS1370C01
HMS560O22
FT-0662224
FT-0662225
3-(phenylcarbamoyl)propanoic acid
4-oxo-4-phenylaminobutanoic acid
CCG-44906
unii-l4v0g8222e
4-12-00-00468 (beilstein handbook reference)
l4v0g8222e ,
SCHEMBL94252
l-000341257
succinanilic acid [mi]
KTFGFGGLCMGYTP-UHFFFAOYSA-N
succinanilsaure
cambridge id 5133967
BBL036006
DTXSID20144511
J-000635
mfcd00029825
SR-01000418000-1
sr-01000418000
Z56176896
4-(phenylamino)-4-oxobutanoic acid
AS-32051
A896886
4-oxo-4-(phenylamino)butanoicacid
Q27282710
4-anilino-4-oxobutanoicacid
CS-W010689

Drug Classes (1)

ClassDescription
anilideAny aromatic amide obtained by acylation of aniline.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Sus scrofa (pig)IC50 (µMol)192.00000.01500.61352.5000AID34780
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID466505Cytotoxicity against human Molt4/C8 cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID466506Cytotoxicity against human CEM cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID34780Inhibition of pig kidney aldose reductase (ALR2)2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Rational design of an indolebutanoic acid derivative as a novel aldose reductase inhibitor based on docking and 3D QSAR studies of phenethylamine derivatives.
AID466507Cytotoxicity against mouse L1210 cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]